Heron Therapeutics Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Heron Therapeutics Inc |
Stock Symbol : | NASDAQ: HRTX |
Class Period Start: | 10/31/2018 |
Class Period End: | 04/30/2019 |
Lead Plaintiff motion: | 08/05/2019 |
Date Filed: | 06/03/2019 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the Southern District of California |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the August 5, 2019 lead plaintiff deadline in a class action lawsuit filed against Heron Therapeutics Inc (NASDAQ: HRTX) (“Heron Therapeutics” or “the Company”). The suit is pending in the U.S. District Court for the Southern District of California and investors, who purchased Heron Therapeutics Inc securities between October 31, 2018 and April 30, 2019, have until August 5, 2019 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Heron Therapeutics Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Heron had failed to include adequate Chemistry, Manufacturing, and Controls and non-clinical information in its New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) for HTX-011; the foregoing increased the likelihood that the FDA would not approve Heron’s NDA for HTX-011; and as a result, Heron’s public statements were materially false and misleading at all relevant times. On May 1, 2019, the Company revealed receipt of a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration on April 30, 2019 regarding Heron’s New Drug Application for HTX-011 for the management of postoperative pain. Heron advised investors that “the CRL stated that the FDA is unable to approve the NDA in its present form based on the need for additional [Chemistry, Manufacturing, and Controls] and non-clinical information.” Following this news, Heron’s stock price fell $3.93 per share, or 18.13%, to close at $17.75 per share on May 1, 2019. If you were negatively impacted by your investment in Heron Therapeutics Inc securities between October 31, 2018 and April 30, 2019 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Materials are provided for informational purposes only and do not constitute legal advice. We are only licensed to practice law in Germany. We are neither licensed nor qualified to render advice on US Federal or State law. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |